Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Unknown 4Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 4Lymphoma, B-Cell 1Advanced Non-small Cell Lung Cancer 1

Interventions

Carboplatin 84Cisplatin 79Pemetrexed 72Docetaxel 62Drug Therapy 44Gemcitabine 43Erlotinib Hydrochloride 42Gefitinib 38Radiotherapy 36Paclitaxel 36pembrolizumab 31Bevacizumab 29icotinib 28osimertinib 27anlotinib 26Nivolumab 26camrelizumab 23Vinorelbine 23Radiosurgery 20aumolertinib 18atezolizumab 17sintilimab 16apatinib 16Endostatins 16endostar protein 15durvalumab 14Surgical Procedures, Operative 13Immunotherapy 13Immune Checkpoint Inhibitors 12Blood Specimen Collection 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Non-Small-Cell Lung × abivertinib × Clear all
NCT03574402 2022-12-06

TRUMP

Guangdong Association of Clinical Trials

Phase 2 Unknown
400 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02330367 2021-09-10

Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC

Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Phase 1/2 Unknown
368 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03300115 2019-02-19

Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC

Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Phase 2 Unknown
222 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02274337 2016-11-23

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer

Sun Yat-sen University

Phase 1/2 Unknown
100 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡